Related Experiment Videos
The immune response modifier resiquimod mimics CD40-induced B cell activation
G A Bishop1, L M Ramirez, M Baccam
1Department of Microbiology, VA Medical Center, Iowa City, Iowa 52242, USA. gail-bishop@uiowa.edu
Cellular Immunology
|March 30, 2001
Summary
Resiquimod, an imidazoquinoline, activates B lymphocytes, mimicking CD40 signals. This immune stimulation suggests its potential as a vaccine adjuvant to enhance antibody responses.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Imidazoquinolines like imiquimod and resiquimod exhibit antiviral and antitumor properties.
- Resiquimod activates monocytes and dendritic cells, but also stimulates B lymphocyte proliferation and activation.
- This B cell activation suggests resiquimod's potential as a vaccine adjuvant for humoral immune responses.
Purpose of the Study:
- To investigate resiquimod's effects on B lymphocytes.
- To determine if resiquimod can mimic T-dependent CD40 signals in B cells.
- To assess resiquimod's potential as a vaccine adjuvant.
Main Methods:
- Utilized mouse and human B cell lines.
- Compared resiquimod's effects to CD40 signaling.
- Assessed B cell proliferation, antibody secretion, cytokine production, apoptosis resistance, and CD80 upregulation.
- Investigated synergy with B cell antigen receptor and CD40-mediated activation.
Main Results:
- Resiquimod mimics CD40 signaling in B cells, inducing antibody secretion, cytokine production, and CD80 upregulation.
- Resiquimod protects B cells from apoptosis.
- Resiquimod exhibits synergy with B cell receptor and CD40 signals, enhancing antigen-specific responses.
Conclusions:
- Resiquimod effectively mimics CD40 signaling in B lymphocytes.
- Resiquimod enhances B cell activation and antigen-specific responses.
- Resiquimod demonstrates significant potential as a vaccine adjuvant for stimulating humoral immunity.